You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Details for Patent: 9,180,125

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,180,125 protect, and when does it expire?

Patent 9,180,125 protects RELISTOR and is included in two NDAs.

This patent has thirty-eight patent family members in eighteen countries.

Summary for Patent: 9,180,125

Title:	Peripheral opioid receptor antagonists and uses thereof
Abstract:	The present invention provides a compound of formula I: ##STR00001## wherein X.sup.-, R.sup.1, and R.sup.2 are as defined herein, and compositions thereof.
Inventor(s):	Bazhina; Nataliya (Tappan, NY), Donato, III; George Joseph (Swarthmore, PA), Fabian; Steven R. (Barnegat, NJ), Lokhnauth; John (Fair Lawn, NJ), Megati; Sreenivasulu (New City, NY), Melucci; Charles (Highland Mills, NY), Ofslager; Christian (Newburgh, NY), Patel; Niketa (Lincoln Park, NJ), Radebaugh; Galen (Chester, NJ), Shah; Syed M. (Delray Beach, FL), Szeliga; Jan (Croton On Hudson, NY), Zhang; Huyi (Garnerville, NY), Zhu; Tianmin (Monroe, NY)
Assignee:	Wyeth, LLC (Madison, NJ)
Application Number:	14/322,382
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,180,125
Patent Claim Types: see list of patent claims	Composition; Compound; Formulation; Use;

Drugs Protected by US Patent 9,180,125

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix Pharms	RELISTOR	methylnaltrexone bromide	SOLUTION;SUBCUTANEOUS	021964-002	Sep 27, 2010	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF OPIOID-INDUCED CONSTIPATION	⤷ Sign Up
Salix Pharms	RELISTOR	methylnaltrexone bromide	SOLUTION;SUBCUTANEOUS	021964-001	Apr 24, 2008		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF OPIOID-INDUCED CONSTIPATION	⤷ Sign Up
Salix Pharms	RELISTOR	methylnaltrexone bromide	SOLUTION;SUBCUTANEOUS	021964-003	Sep 27, 2010	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF OPIOID-INDUCED CONSTIPATION	⤷ Sign Up
Salix	RELISTOR	methylnaltrexone bromide	TABLET;ORAL	208271-001	Jul 19, 2016		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF OPIOID-INDUCED CONSTIPATION	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,180,125

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	073520	⤷ Sign Up
Australia	2009298500	⤷ Sign Up
Brazil	122020013665	⤷ Sign Up
Brazil	PI0919539	⤷ Sign Up
Canada	2676881	⤷ Sign Up
China	102307874	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.